• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。

Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.

机构信息

Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.

School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.

出版信息

Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.

DOI:10.1016/j.ijantimicag.2019.02.022
PMID:30831233
Abstract

Pseudomonas aeruginosa is one of the most important pathogens in cystic fibrosis. This study was conducted to analyse the genetic basis and phylogenetic profile of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in cystic fibrosis P. aeruginosa isolates. Whole genome sequence analysis was conducted of isolates resistant to piperacillin/tazobactam collected from seven hospitals in Scotland since the introduction of these two cephalosporin/β-lactamase inhibitor combinations. Ceftazidime resistance was primarily related to AmpC induction, as tested by cloxacillin inhibition assays, while high-level ceftazidime resistance not reversed by cloxacillin was associated with amino acid variations in AmpC. Only isolates resistant to both ceftazidime/avibactam and ceftolozane/tazobactam carried AmpD mutations, likely resulting in ampC overexpression. All isolates resistant to ceftazidime/avibactam and/or ceftolozane/tazobactam were resistant to carbapenems and showed inactivating mutations in the chromosomal oprD gene. None of the isolates bore class A, B, D plasmid-encoded carbapenemases. This study showed that mutational resistance emerged in phylogenetically distant lineages, which indicates the mutations occur independently without conferring a selective advantage to any phylogenetic lineage. These findings confirm the strong contribution of mutation-driven evolution to the population structure of P. aeruginosa.

摘要

铜绿假单胞菌是囊性纤维化的最重要病原体之一。本研究旨在分析囊性纤维化铜绿假单胞菌分离株对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药的遗传基础和系统发育特征。对苏格兰 7 家医院自这两种头孢菌素/β-内酰胺酶抑制剂组合引入以来分离出的对哌拉西林/他唑巴坦耐药的菌株进行了全基因组序列分析。头孢他啶耐药主要与 AmpC 诱导有关,通过氯唑西林抑制试验进行检测,而不能被氯唑西林逆转的高水平头孢他啶耐药与 AmpC 中的氨基酸变异有关。只有对头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦均耐药的分离株携带 AmpD 突变,可能导致 ampC 过表达。所有对头孢他啶/阿维巴坦和/或头孢洛扎/他唑巴坦耐药的分离株均对碳青霉烯类药物耐药,并在染色体 oprD 基因中显示出失活突变。没有分离株携带 A、B、D 类质粒编码的碳青霉烯酶。本研究表明,突变耐药出现在系统发育上较远的谱系中,这表明突变是独立发生的,不会赋予任何系统发育谱系选择性优势。这些发现证实了突变驱动的进化对铜绿假单胞菌种群结构的强烈贡献。

相似文献

1
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
2
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.ERACE-PA 全球监测计划:头孢他啶/他唑巴坦和头孢他啶/阿维巴坦对全球碳青霉烯类耐药铜绿假单胞菌的体外活性。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541. doi: 10.1007/s10096-021-04308-0. Epub 2021 Jul 22.
3
Integrated Genome-Wide Analysis of an Isogenic Pair of Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.临床分离株对头孢洛扎他唑巴坦、头孢他啶/阿维巴坦和哌拉西林/他唑巴坦的抗菌药物耐药性差异的同源对全基因组综合分析。
Int J Mol Sci. 2020 Feb 4;21(3):1026. doi: 10.3390/ijms21031026.
4
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.对治疗过程中对头孢洛扎/他唑巴坦产生耐药性的广泛耐药铜绿假单胞菌分离株中的 AmpC β-内酰胺酶突变进行表征。
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec;38(10):474-478. doi: 10.1016/j.eimc.2020.01.017. Epub 2020 Mar 3.
5
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.土耳其碳青霉烯类耐药铜绿假单胞菌临床分离株中头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦和头孢地尔的药敏谱。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1787-1794. doi: 10.1007/s10096-024-04896-7. Epub 2024 Jul 12.
6
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in .产超广谱β-内酰胺酶 GES-6 的获得导致. 对头孢洛扎他巴坦联合制剂的耐药性
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01809-18. Print 2019 Jan.
7
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.大肠埃希菌和铜绿假单胞菌中产 ESBLs 对头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦组合的耐药性。
J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939. doi: 10.1093/jac/dkz149.
8
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.评估头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦对来自卡塔尔的多重耐药铜绿假单胞菌分离株的体外活性。
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504. doi: 10.1093/jac/dkz379.
9
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.在治疗多重耐药/广泛耐药铜绿假单胞菌感染期间,导致头孢洛扎他/他唑巴坦和头孢他啶/阿维巴坦耐药的 AmpC β-内酰胺酶变体和金属β-内酰胺酶的选择。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20.
10
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.头孢他洛滨-他唑巴坦对产碳青霉烯酶非产碳青霉烯酶耐药铜绿假单胞菌的活性及相关耐药机制。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01970-17. Print 2018 Jan.

引用本文的文献

1
Ceftazidime-Induced Overexpression of MexJK-OprM Confers Resistance to Ceftolozane/Tazobactam in an Isolate of .头孢他啶诱导MexJK-OprM过表达使一株[细菌名称未给出]分离株对头孢洛扎/他唑巴坦产生耐药性。
Infect Drug Resist. 2025 Aug 8;18:3947-3956. doi: 10.2147/IDR.S540567. eCollection 2025.
2
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.针对多重耐药和碳青霉烯耐药革兰氏阴性菌的新型抗生素:作用机制与耐药机制
Arch Microbiol. 2025 Apr 2;207(5):110. doi: 10.1007/s00203-025-04298-z.
3
High ceftazidime-avibactam resistance rate in carbapenem-resistant gram-negative organisms in Pakistan's pediatric population.
巴基斯坦儿科人群中耐碳青霉烯革兰氏阴性菌对头孢他啶-阿维巴坦的耐药率较高。
Pak J Med Sci. 2025 Mar;41(3):788-791. doi: 10.12669/pjms.41.3.9978.
4
In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains.头孢他啶-阿维巴坦/氨曲南联合用药对产金属β-内酰胺酶铜绿假单胞菌菌株的体外活性
Infection. 2024 Nov 18. doi: 10.1007/s15010-024-02425-4.
5
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.比较多药耐药铜绿假单胞菌所致非 COVID-19 肺炎患者用头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦早期治疗的效果。
J Antimicrob Chemother. 2024 Nov 4;79(11):2954-2964. doi: 10.1093/jac/dkae313.
6
Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing .智利非产碳青霉烯酶. 临床分离株中,产 PER-3 的 ST309 谱系与头孢他啶/阿维巴坦耐药相关。
Front Cell Infect Microbiol. 2024 Jun 5;14:1410834. doi: 10.3389/fcimb.2024.1410834. eCollection 2024.
7
Genetic determinants of antimicrobial resistance in polymyxin B resistant Pseudomonas aeruginosa isolated from airways of patients with cystic fibrosis.多粘菌素 B 耐药铜绿假单胞菌分离自囊性纤维化患者气道中的抗生素耐药基因决定簇。
Braz J Microbiol. 2024 Jun;55(2):1415-1425. doi: 10.1007/s42770-024-01311-3. Epub 2024 Apr 15.
8
Acetylcysteine increases sensitivity of ceftazidime-avibactam-resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo.乙酰半胱氨酸增加了不同酶耐药性的头孢他啶-阿维巴坦耐药肠杆菌科对头孢他啶-阿维巴坦的体外和体内敏感性。
BMC Microbiol. 2023 Nov 3;23(1):321. doi: 10.1186/s12866-023-03068-5.
9
What to Do with the New Antibiotics?如何应对新型抗生素?
Antibiotics (Basel). 2023 Mar 27;12(4):654. doi: 10.3390/antibiotics12040654.
10
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of from five Latin American countries.来自五个拉丁美洲国家的临床分离株中导致头孢洛扎/他唑巴坦耐药的分子机制。
Front Microbiol. 2022 Oct 24;13:1035609. doi: 10.3389/fmicb.2022.1035609. eCollection 2022.